4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001470831-26-000700
Chief Financial Officer sold 28,000 shares at an average $28.85 ($807,672)
- Chief Financial Officer acquired 12,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Option exercise 10b5-1 | +12,500 | $3.79 | $47,373 | 157,855 | D |
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Sale 10b5-1 | −22,757 | $28.60 | $650,896 | 135,098 | D |
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Sale 10b5-1 | −4,413 | $29.82 | $131,616 | 130,685 | D |
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Sale 10b5-1 | −830 | $30.31 | $25,160 | 129,855 | D |
| Derivatives | |||||||
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,592 | 58,992 | D | ||
| Hyep Ivan Chief Financial Officer | 2026-07-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −908 | 38,836 | D | ||
| Open-market sales · 28,000 sh · avg $28.85 · $807,672 | |||||||
Loading xslF345X06/wk-form4_1783714240.xml…